eMed IPO status, timeline, valuation and S-1 filing tracker. Last updated August 2026.
| Industry | Health Tech |
| Stage | Late Stage Private |
| IPO Status | Pre-IPO |
| Valuation | $3.5B |
| Total Funding | $592M |
| Headquarters | United States |
| IPO Readiness Score | 71/100 |
| Founded | 2020 |
Track eMed IPO status, valuation updates, and S-1 filing milestones on TechStackIPO. Last updated August 2026.
AI-managed healthcare platform specializing in GLP-1 weight health, decentralized clinical trials, and remote diagnostic testing.
eMed is in the pre-IPO phase as of August 2026. With an IPO readiness score of 71/100, the company ranks among the more IPO-ready companies in the Health Tech sector. Pre-IPO companies at this stage typically evaluate market conditions, complete board appointments, and engage underwriters before initiating the formal S-1 filing process.
eMed is valued at $3.5B based on the most recent private market data. The company has raised a total of $592M in funding. Private market valuations are determined by the latest funding round and may differ from eventual IPO pricing, which reflects public market conditions, investor demand, and comparable company multiples at the time of listing.
Funding rounds from seed through latest — Series A, B, C and beyond.
| Round | Date | Amount | Valuation | Lead Investor(s) |
|---|---|---|---|---|
| Series A | Apr 2026 | $200M | $2B+ | Aon Consulting |
| Series D | Jul 2026 | $250M | — | — |
Total funding raised: $592M
Bear / base / bull scenarios based on current private market valuation and comparable IPO multiples.
| Scenario | Est. Valuation | Basis |
|---|---|---|
| Bear | $2.6B | Compressed multiples, delayed listing |
| Base | $3.5B | Last private round valuation |
| Bull | $4.9B | Strong market, premium AI/tech multiple |
Estimates are illustrative. Not investment advice. All figures based on publicly available data.
eMed has an IPO readiness score of 71/100 on TechStackIPO. A high readiness score suggests IPO activity could occur within the next 1–2 years.
eMed's last known private valuation is $3.5B. IPO valuations typically reflect current market conditions at time of listing and may differ from private market valuations.
Pre-IPO access options may include: (1) secondary market platforms such as Forge Global or EquityZen that facilitate private share sales, (2) ETFs holding pre-IPO companies or venture portfolios, and (3) direct secondary share purchases if eligible as an accredited investor. TechStackIPO tracks availability but does not facilitate investments.
No. eMed has not yet filed an S-1 registration statement with the SEC as of TechStackIPO's latest data update.
eMed operates in the Health Tech sector. TechStackIPO tracks multiple Health Tech companies from seed through IPO, including their funding rounds, valuations, and IPO readiness scores. You can compare eMed against other Health Tech companies using TechStackIPO's comparison tool.
eMed is at the Late Stage Private stage. The company has raised a total of $592M in funding. Companies at this funding stage are typically scaling operations, expanding market share, and evaluating public market timing.
eMed is headquartered in United States. The company's location can influence IPO exchange selection, regulatory requirements, and investor interest. Companies headquartered in major tech hubs often benefit from proximity to venture capital networks and talent pools.